



Supplemental Figure 1



Supplemental Figure 1 PPP2R2A deficiency in T cells decreases IFN- γ - and IL-17A-positive T cells in splenocytes. Splenocytes isolated from R2A^{fl/fl} or Lck^{Cre}R2A^{fl/fl} mice were stimulated using PMA/ionomycin for 4 hours before FACS analysis. **(A)** Representative flow cytometry plots are shown. **(B)** Cumulative data ($n = 6$ mice/group) depicting proliferation the percentages of IFN- γ - and IL-17-positive cells. * $P < 0.05$ and **** $P < 0.0001$ by unpaired T test. The data were obtained from three independent experiments.

Supplemental Figure 2



Supplemental Figure 2 PPP2R2A deficiency does not alter the phosphorylation status of SMAD2 and SMAD3. R2A^{fl/fl} and Lck^{Cre}R2A^{fl/fl} naive CD4⁺ T cells were cultured under Th17-polarizing condition for 3 days *in vitro* before analysis. Protein lysates were prepared for western blot analysis using the indicated antibodies. (A) immunoblot; (B) cumulative data (n=4 mice/group). The data were obtained from two independent experiments.

Supplemental Table 1 Antibodies used for FACS.

Antibody-Conjugate	Company (clone)	Dilution
Figure 3		
CD3-PE/Cy7	BioLegend (17A2)	1:100
CD4-Percp/Cy5.5	BioLegend (GK1.5)	1:100
CD8-APC/Cy7	BD Pharmingen (53-6.7)	1:100
Figure 4B		
CD4-PE/Cy7	BioLegend (RM4-5)	1:100
IFN- γ -Bv421 (Th1)	BioLegend (XMG1.2)	1:50
IL-17A-PE (Th17)	BioLegend (TC11-18H10.1)	1:50
or Foxp3-PE (Treg)	eBioscience (FJK-16s)	1:50
Figure 6		
CD45-APC	BioLegend (30-F11)	1:100
CD4-PercpFloor 710	Invitrogen (SK3)	1:100
CD8-FITC	BioLegend (53-6.7)	1:100
Thy1.2-PE/Cy7	BioLegend (53-2.1)	1:100
IL-17A-PE	BioLegend (TC11-18H10.1)	1:50
IFN- γ -Bv421	BioLegend (XMG1.2)	1:50
Supplemental Figure 1		
CD3-PE/Cy7	BioLegend (17A2)	1:100
IFN- γ -Bv421 (Th1)	BioLegend (XMG1.2)	1:50
IL-17A-PE (Th17)	BioLegend (TC11-18H10.1)	1:50